Mopidamol

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-106618 13665-88-8 C ₁₉ H ₃₁ N ₇ O ₄ 421.49 Phosphodiesterase (PDE) Metabolic Enzyme/Protease Please store the product under the recommended conditions in the Certificate of Analysis.	
---	--	--

BIOLOGICAL ACTIVITY

Description Mopidamol (RA 233), a derivative of Dipyridamole (HY-B0312), is a phosphodiesterase inhibitor. RA-233 can be used for nonsmall cell lung cancer (N-SCLC) research^{[1][2]}.

REFERENCES

[1]. Eliasson R, Bygdeman S. Effect of dipyridamole and two pyrimido-pyrimidine derivatives on the kinetics of human platelet aggregation and on platelet adhesiveness. Scand J Clin Lab Invest. 1969 Sep;24(2):145-51.

[2]. Zacharski LR, et al. Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188. J Natl Cancer Inst. 1988 Mar 16;80(2):90-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Product Data Sheet

MedChemExpress